• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Reflecting on my Son’s Graduation as a Previvor

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles As a Lynch syndrome previvor, I feel deep gratitude to witness my son’s graduation — a milestone my brother never lived to see with his own child. Read More

First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity. Read More

Study Reveals Distinct Outcomes in Younger Patients With Grade 3 Oligodendroglioma

by MM360 Staff | May 19, 2025 | Uncategorized

Source: CureToday articles Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a study found. Read More

Fatigue, Sleep and Urinary Symptoms Affect Cognition in Prostate Cancer

by MM360 Staff | May 18, 2025 | Uncategorized

Source: CureToday articles Managing fatigue, sleep, urinary symptoms and depression is key to improving cognitive function in those receiving radiation therapy for prostate cancer. Read More

Providing Care and Listening With Compassion During Cancer

by MM360 Staff | May 18, 2025 | Uncategorized

Source: CureToday articles Post Content Read More

Tagrisso Therapy Elicits Wave of New Therapeutic Approaches in NSCLC

by MM360 Staff | May 17, 2025 | Uncategorized

Source: CureToday articles Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC. Read More
« Older Entries
Next Entries »

Recent Content

  • I Sometimes Forget to Celebrate Survivorship
  • Policy Shifts Ahead: Expert Reviews Key Legislative Trends Reshaping Health-System Pharmacy
  • A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma
  • Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC
  • You Are Not Alone While Building a Support Team During Cancer Care
  • Community Pharmacist Collaboration Expands Access to Long-Acting Injectable Antipsychotics
  • Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
  • ASCO 2025: Promising Safety and Efficacy of Encorafenib and Binimetinib in Resected Stage II Melanoma
  • When Treatment Ends, Support Shouldn’t Stop in Cancer Care
  • New Online Competency Modules Standardize CPA Pharmacist Training at Academic Medical Center
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT